752240-01-0

752240-01-0 structure

Name: MK-0941 free base
Chemical Name: MK-0941 free base
CAS Number: 752240-01-0
Molecular Formula: C₂₁H₂₄N₄O₆S
Molecular Weight: 460.50
Catalog: Signaling Pathways Metabolic Enzyme/Protease Glucokinase
Create Date: 2019-10-06 12:09:36
Modify Date: 2024-01-19 18:10:07
MK-0941 free base is an orally active glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes[1][2].

Name	MK-0941 free base

Description	MK-0941 free base is an orally active glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Glucokinase Research Areas >> Metabolic Disease
Target	Glucokinase[1][2].
In Vivo	MK-0941 free base (3 or 10 mg/kg, sing oral dose) treatment reduced blood glucose significantly in db/db diabetic mouse[1]. Animal Model: Male db/db and db/+ (lean) mice (9-10 weeks of age, weighing 43-45 g) [1]. Dosage: 3 or 10 mg/kg. Administration: Oral gavage, single dose. Result: Resulted in significant reduction in blood glucose. These two doses lowered blood glucose similarly at 1 h after dosing, suggesting that saturation of effect was approached.
References	[1]. Eiki J, et al. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol. 2011 Dec;80(6):1156-65. [2]. Meininger GE, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care. 2011 Dec;34(12):2560-6.

Molecular Formula	C₂₁H₂₄N₄O₆S
Molecular Weight	460.50